In patients with chronic kidney disease or those on potassium supplements or potassium-sparing drugs, the risk for hyperkalemia increases and requires monitoring.

Due to the primary method of metabolism for azilsartan being CYP2C9, once therapy has started, interactions with strong modulators of CYP2C9 should be monitored closely.